"Thrombocytopenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subnormal level of BLOOD PLATELETS.
| Descriptor ID |
D013921
|
| MeSH Number(s) |
C15.378.140.855
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thrombocytopenia".
Below are MeSH descriptors whose meaning is more specific than "Thrombocytopenia".
This graph shows the total number of publications written about "Thrombocytopenia" by people in this website by year, and whether "Thrombocytopenia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 2 | 3 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 2 | 2 | 4 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 3 | 3 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 0 | 4 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 4 | 5 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 3 | 4 |
| 2017 | 2 | 2 | 4 |
| 2018 | 2 | 2 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 5 | 4 | 9 |
| 2021 | 8 | 3 | 11 |
| 2022 | 6 | 0 | 6 |
| 2023 | 6 | 0 | 6 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thrombocytopenia" by people in Profiles.
-
Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition. Blood. 2024 10 24; 144(17):1765-1780.
-
Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia. J Stroke Cerebrovasc Dis. 2024 Jun; 33(6):107310.
-
Natural history study of patients with familial platelet disorder with associated myeloid malignancy. Blood. 2023 12 21; 142(25):2146-2158.
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol. 2024 Jan; 25(1):29-45.
-
SERUM HUMANIN IN PEDIATRIC SEPTIC SHOCK-ASSOCIATED MULTIPLE-ORGAN DYSFUNCTION SYNDROME. Shock. 2024 Jan 01; 61(1):83-88.
-
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.
-
Treatment of thrombocytopenia and thrombosis in HIT in mice using deglycosylated KKO: a novel therapeutic? Blood Adv. 2023 08 08; 7(15):4112-4123.
-
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023 Apr; 10(4):e272-e283.
-
Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies. Blood. 2022 12 22; 140(25):2722-2729.
-
Ancestry, ACKR1 and leucopenia in patients with systemic lupus erythematosus. Lupus Sci Med. 2022 11; 9(1).